Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Griesshammer, 2015, Current and future treatment options for polycythemia vera, Ann Hematol, 94, 901, 10.1007/s00277-015-2357-4 Spivak, 2018, Polycythemia Vera, Curr Treat Options Oncol, 19, 12, 10.1007/s11864-018-0529-x Stein, 2015, Polycythemia Vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F, J Clin Oncol, 33, 3953, 10.1200/JCO.2015.61.6474 Hasselbalch, 2019, Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?, Semin Immunopathol, 41, 5, 10.1007/s00281-018-0700-2 Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders, N Engl J Med, 352, 1779, 10.1056/NEJMoa051113 Tefferi, 2015, Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice, Mayo Clin Proc, 90, 1283, 10.1016/j.mayocp.2015.05.014 Vainchenker, 2017, Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms, Blood, 129, 667, 10.1182/blood-2016-10-695940 Kiladjian, 2006, High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a, Blood, 108, 2037, 10.1182/blood-2006-03-009860 Kiladjian, 2008, Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera, Blood, 112, 3065, 10.1182/blood-2008-03-143537 King, 2015, Comparative long-term effects of interferon alpha and hydroxyurea on human hematopoietic progenitor cells, Exp Hematol, 43, 912, 10.1016/j.exphem.2015.05.013 Masarova, 2017, Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial, Lancet Haematol, 4, e165, 10.1016/S2352-3026(17)30030-3 Quintas-Cardama, 2009, Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera, J Clin Oncol, 27, 5418, 10.1200/JCO.2009.23.6075 Silver, 2013, Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis, Expert Rev Hematol, 6, 49, 10.1586/ehm.12.69 Tashi, 2018, Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses, Leukemia, 32, 1830, 10.1038/s41375-018-0080-6 Them, 2015, Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b, Am J Hematol, 90, 288, 10.1002/ajh.23928 Verger, 2018, Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo, Blood Cancer J, 8, 94, 10.1038/s41408-018-0133-0 Silver, 2016, Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials, Hematology, 21, 387, 10.1080/10245332.2015.1111644 Quintas-Cardama, 2013, Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a, Blood, 122, 893, 10.1182/blood-2012-07-442012 Gisslinger, 2015, Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera, Blood, 126, 1762, 10.1182/blood-2015-04-637280 Jabbour, 2007, PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study, Cancer, 110, 2012, 10.1002/cncr.23018 Silver, 2006, Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha, Cancer, 107, 451, 10.1002/cncr.22026 Heis, 1999, The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera, Eur J Haematol, 62, 27, 10.1111/j.1600-0609.1999.tb01110.x Gisslinger, 1989, Long-term interferon therapy for thrombocytosis in myeloproliferative diseases, Lancet, 1, 634, 10.1016/S0140-6736(89)92142-9 Alvarez-Larrán, 2012, Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera, Blood, 119, 1363, 10.1182/blood-2011-10-387787 Alvarez-Larrán, 2016, Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes, Eur J Haematol, 96, 83, 10.1111/ejh.12552 Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, 114, 937, 10.1182/blood-2009-03-209262 Barosi, 2009, Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference, Blood, 113, 4829, 10.1182/blood-2008-09-176818 Mascarenhas, 2018, Blood, 132, 577, 10.1182/blood-2018-99-111946 Samuelsson, 2006, A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life, Cancer, 106, 2397, 10.1002/cncr.21900 Mullally, 2016, Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms, Pathologe, 37, 175, 10.1007/s00292-016-0240-2 Kralovics, 2008, Genetic complexity of myeloproliferative neoplasms, Leukemia, 22, 1841, 10.1038/leu.2008.233 Kiladjian, 2016, Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone, Leukemia, 30, 776, 10.1038/leu.2015.326 Gisslinger, 2018, Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with ropeginterferon alfa-2b vs. HU/BAT, Blood, 132, 579, 10.1182/blood-2018-99-118715 Vannucchi, 2007, Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden, Leukemia, 21, 1952, 10.1038/sj.leu.2404854 Cuthbert, 2019, Therapy-associated leukemic transformation in myeloproliferative neoplasms—What do we know?, Best Pract Res Clin Haematol, 32, 65, 10.1016/j.beha.2019.02.004